Cargando…
Serum YKL-40 Levels and Chitotriosidase Activity in Patients with Beta-Thalassemia Major
Background. YKL-40 association with human disease has been the object of many years of investigation. β-thalassemia patients are affected by hepatic siderosis, which determines a fibrotic process and tissue remodelling. Chitotriosidase has been found to be increased in thalassemic patients returning...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997983/ https://www.ncbi.nlm.nih.gov/pubmed/24808626 http://dx.doi.org/10.1155/2014/965971 |
_version_ | 1782313275108622336 |
---|---|
author | Musumeci, Maria Caruso, Vincenzo Medulla, Emilia Torrisi, Venerando Migale, Roberta Angeletti, Silvia Musumeci, Salvatore |
author_facet | Musumeci, Maria Caruso, Vincenzo Medulla, Emilia Torrisi, Venerando Migale, Roberta Angeletti, Silvia Musumeci, Salvatore |
author_sort | Musumeci, Maria |
collection | PubMed |
description | Background. YKL-40 association with human disease has been the object of many years of investigation. β-thalassemia patients are affected by hepatic siderosis, which determines a fibrotic process and tissue remodelling. Chitotriosidase has been found to be increased in thalassemic patients returning to normal in patients submitted to bone marrow transplantation. YKL-40 is associated with macrophage activation in liver and in other tissues. The aim of the study was to analyse the level of serum YKL-40 and plasma chitotriosidase activity of patients with beta-thalassemia to assess whether their expression correlates with liver disease and degree of liver siderosis. Methods. Expression of YKL-40 and chitotriosidase as a marker of inflammation in 69 thalassemic patients were evaluated. We sought to investigate whether these two chitinases could be considered as a significant biomarker to evaluate therapy effectiveness. Results. Surprisingly we found normal value of YKL-40. We, also, analysed chitotriosidase activity in the same patients that was slightly increased as a consequence of macrophage activation. Conclusions. These data would suggest a good treatment for these patients. |
format | Online Article Text |
id | pubmed-3997983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-39979832014-05-07 Serum YKL-40 Levels and Chitotriosidase Activity in Patients with Beta-Thalassemia Major Musumeci, Maria Caruso, Vincenzo Medulla, Emilia Torrisi, Venerando Migale, Roberta Angeletti, Silvia Musumeci, Salvatore Dis Markers Research Article Background. YKL-40 association with human disease has been the object of many years of investigation. β-thalassemia patients are affected by hepatic siderosis, which determines a fibrotic process and tissue remodelling. Chitotriosidase has been found to be increased in thalassemic patients returning to normal in patients submitted to bone marrow transplantation. YKL-40 is associated with macrophage activation in liver and in other tissues. The aim of the study was to analyse the level of serum YKL-40 and plasma chitotriosidase activity of patients with beta-thalassemia to assess whether their expression correlates with liver disease and degree of liver siderosis. Methods. Expression of YKL-40 and chitotriosidase as a marker of inflammation in 69 thalassemic patients were evaluated. We sought to investigate whether these two chitinases could be considered as a significant biomarker to evaluate therapy effectiveness. Results. Surprisingly we found normal value of YKL-40. We, also, analysed chitotriosidase activity in the same patients that was slightly increased as a consequence of macrophage activation. Conclusions. These data would suggest a good treatment for these patients. Hindawi Publishing Corporation 2014 2014-04-08 /pmc/articles/PMC3997983/ /pubmed/24808626 http://dx.doi.org/10.1155/2014/965971 Text en Copyright © 2014 Maria Musumeci et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Musumeci, Maria Caruso, Vincenzo Medulla, Emilia Torrisi, Venerando Migale, Roberta Angeletti, Silvia Musumeci, Salvatore Serum YKL-40 Levels and Chitotriosidase Activity in Patients with Beta-Thalassemia Major |
title | Serum YKL-40 Levels and Chitotriosidase Activity in Patients with Beta-Thalassemia Major |
title_full | Serum YKL-40 Levels and Chitotriosidase Activity in Patients with Beta-Thalassemia Major |
title_fullStr | Serum YKL-40 Levels and Chitotriosidase Activity in Patients with Beta-Thalassemia Major |
title_full_unstemmed | Serum YKL-40 Levels and Chitotriosidase Activity in Patients with Beta-Thalassemia Major |
title_short | Serum YKL-40 Levels and Chitotriosidase Activity in Patients with Beta-Thalassemia Major |
title_sort | serum ykl-40 levels and chitotriosidase activity in patients with beta-thalassemia major |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997983/ https://www.ncbi.nlm.nih.gov/pubmed/24808626 http://dx.doi.org/10.1155/2014/965971 |
work_keys_str_mv | AT musumecimaria serumykl40levelsandchitotriosidaseactivityinpatientswithbetathalassemiamajor AT carusovincenzo serumykl40levelsandchitotriosidaseactivityinpatientswithbetathalassemiamajor AT medullaemilia serumykl40levelsandchitotriosidaseactivityinpatientswithbetathalassemiamajor AT torrisivenerando serumykl40levelsandchitotriosidaseactivityinpatientswithbetathalassemiamajor AT migaleroberta serumykl40levelsandchitotriosidaseactivityinpatientswithbetathalassemiamajor AT angelettisilvia serumykl40levelsandchitotriosidaseactivityinpatientswithbetathalassemiamajor AT musumecisalvatore serumykl40levelsandchitotriosidaseactivityinpatientswithbetathalassemiamajor |